This is a single-arm pilot study in Peking Union Medical College Hospital. Telitacicept will
be added on traditional antithrombotic and immunosuppressive treatment in primary
antiphospholipid syndrome (APS) patients with three positive antiphospholipid antibodies
(aPL) and at least one extra-criteria manifestations, including thrombocytopenia, autoimmune
hemolytic anemia, aPL associated nephropathy, heart valvular disease, non-stroke neurological
manifestations. This study aims to evaluate the efficacy of Telitacicept in preventing
thrombosis and improving extra-criteria manifestations on high-risk APS patients.